Thymic epithelial cells (TECs), the major component of the thymic microenvironment, can be modulated by pituitary hormones. We have shown previously that prolactin (PRL) can influence the endocrine activity of TECs and stimulate TEC proliferation as well as cytokeratin expression, suggesting the existence of PRL receptors on TECs. Using a series of monoclonal antibodies (mAbs) to the extracellular domain of the rat liver PRL receptor, we have demonstrated that rat TECs bear specific receptors for PRL, as asesed by immunoblotting as well as by immunocytchemisty experiments. Using a probe specific for the long form of PRL receptor, mRNAs of 6.7 and 10.1 kilobases were detected, although by immunoblot the major protein in TECs had a molecular mass of 43 kDa. Functionally, these mAbs were able to modulate thymulin secretion, as well as TEC proliferation. Moreover, the mAbs cross-reacted with human TECs and were able to mimic the action of PRL on these cells. These data bring further support for the general concept of the neuroendocrine immune circuit and extend the notion for a pleiotropic role of PRL as an immunomodulatory hormone.
It is now established that some steps of T-cell differentiation are driven by a group of thymus-derived polypeptides called thymic hormones (1) . One of them, named thymulin (formerly Facteur thymique sdrique or FTS), was described by our group and its amino acid sequence was determined (2) . It is a nonapeptide whose biological activity is dependent on the presence of zinc in an equimolar ratio (3) . More recently, we demonstrated that the metallopeptide thus formed bears a specific tridimensional conformation detected by nuclear magnetic resonance studies (4) that parallels the appearance of a new monoclonal antibody (mAb)-defined epitope (5) . Thymulin is exclusively produced by thymic epithelial cells (TECs) (6) and the intracellular pathway for its secretion apparently follows a classic peptide-secretion model, possibly with exocytosis of secretory vacuoles (7) . Secretion of this thymic hormone is under pleiotropic control, involving not only thymulin itself, but also several other hormones including thyroid and steroid hormones (reviewed in ref. 8) .
It is noteworthy that thymulin production is also influenced by the hypothalamic-pituitary axis. In this respect, we initially showed that the dwarf mouse exhibited a precocious decline in the circulating levels of this thymic hormone (9) . In addition, it was reported that thymulin serum levels were consistently decreased in children with growth hormone (GH) deficiency and that GH therapy restored thymulin levels to normal values (10) . In the same vein, it was shown that GH injected into old dogs restored thymulin levels to young adulthood conditions (11) . Furthermore, we demonstrated that this stimulatory effect could also be obtained in vitro by using human GH on TEC lines (12) . More recently, using binding experiments and autoradiographic procedures, we demonstrated the presence ofGH receptors on TECs (13) . In addition to GH, highly purified prolactin (PRL) is also able to influence TEC functions. First, we showed that PRLinjected mice had a significant increase in thymulin production and that an opposite effect could be obtained in animals treated with bromocriptine, a well known inhibitor of PRL biosynthesis. The stimulatory effect of PRL on thymulin secretion was also observed in vitro by using both primary cultures ofhuman TECs and murine TEC lines. Interestingly, this pituitary hormone apparently has a pleiotropic effect on TECs since it was able to modulate cytokeratin expression and cell proliferation (12 Cultures of TECs. Primary cultures of human TECs were established as described (14) . Briefly, human thymus fragments were minced with fine scissors and left to settle and proliferate within culture slide flasks (Nunc). The rat TEC line was originally produced in T. Itoh's laboratory and was shown to stimulate prothymocyte proliferation and to produce thymic hormones (15) .
Antibodies and Enzyme Revealing System. Five anti-PRL receptor mAbs (T1, T6, U5, U6, and E21) were obtained as detailed elsewhere (16) . These mAbs were produced in BALB/c mice immunized with partially purified PRL receptors from rat liver and were able to precipitate the PRL receptor with molecular masses of 84, 42, and 40 kDa. Goat anti-mouse immunoglobulins (IgG) were purchased from Biosys (Compipgne, France). The anti-bromodeoxyuridine (BrdUrd) mAb was a reagent from Immunotech (Marseille, France) and, as originally described (17) , detects (21) . Briefly, each specimen was first incubated with a given anti-PRL receptor mAb for 1 h, washed in phosphatebuffered saline (PBS), subjected to the 1:500 diluted biotinylated goat anti-rabbit immunoglobulin antibody followed by further PBS washing, and lastly incubated with the streptavidin-peroxidase complex (diluted 1:500) for 1 h and revealed with aminoethylcarbazole in the presence of H202.
Immunoblotting. Extracts (containing 2-mercaptoethanol) were obtained from human and rat thymus fragments as well as the rat TEC line, as described (22) . Briefly, proteins were resolved by SDS/PAGE at room temperature using a LKB power supply fixed at 250 mA. Specimens were then transferred onto nitrocellulose sheets for 2 h at a current of 0.7 A. After saturation of nonspecific protein binding sites with 10%o fetal calf serum diluted in PBS containing 0.1% Tween 20 for 2 h, the bands were incubated with the anti-PRL receptor mAbs (0.1 mg/ml), which were revealed by the biotinylated goat anti-mouse antiserum followed by streptavidinperoxidase complex. Enzyme activity was demonstrated with 3,3'-diaminobenzidine in the presence of H202.
Northern Blot Analysis. RNA was extracted from 1.5 g of cultured rat TECs. Total RNA was purified using the guanidium thiocyanate/CsCl procedure (23) , and polyadenylylated mRNA was purified by oligo(dT)-cellulose chromatography. Poly(A)+ mRNA was treated for 60 min at 50°C and 1 M glyoxal/50o dimethyl sulfoxide/10 mM Na2HPO4, pH 6.5, and run through a 1.5% agarose gel in 10 mM Na2HPO4. A 0.24-to 9.5-kilobase (kb) RNA ladder (Bethesda Research Laboratories) was also included on the gel as molecular size marker. Transfer of RNA, hybridization with specific RNA probes to the short and long forms of PRL receptor, washing, and autoradiography were performed as described (24, 25) .
Thymulin Levels in TEC Culture Supernatants. Thymulin was measured by a bioassay detailed elsewhere (12, 26) . This bioassay is reliable and was shown by us and several other investigators to be strictly thymus specific. It analyzes the effect ofthymulin on restoration of sensitivity to azathioprine of rosette-forming spleen cells from thymectomized mice. Briefly, culture supernatants under study were filtered through Amicon membranes (YMT micropartition system MPS-1, Amicon) to eliminate high molecular weight molecules, which have been previously shown to inhibit thymulin biological activity in the assay. The ultrafiltrates were incubated for 90 min at 37°C with spleen cells from C57BL/6 mice, thymectomized 10-15 days before the test, and treated with azathioprine at 10 ,.g/ml, a concentration that inhibits rosette formation in normal mice but not in thymectomized mice. Rosettes were then formed by centrifugation with sheep erythrocytes and enumerated in a hematocytometer after gentle resuspension. When culture supernatants contained thymulin, rosette formation was inhibited by azathioprine. Since the bioassay is semiquantitative, results are expressed either as the highest dilution or as the log 2 of reciprocal highest dilution of the culture supernatants conferring sensitivity to azathioprine inhibition on spleen cells from adult thymectomized mice. Six samples were tested in eight replicates to determine the intraassay coefficients of variation, which were <10o. All other samples were tested in triplicate. To confirm the specificity of the biological activity measured, determinations were repeated after preincubation of the supernatants under study with an antithymulin mAb.
In Vitro Treatment of TECs. Various anti-PRL receptor mAbs, diluted in the culture medium, were added in vitro to epithelial cells in a concentration range of 10-7-10-11 M. In murine TECs, the antibodies were added at days 0 and 3 after trypsin treatment. In primary human TECs, they were added at days 1 and 3 after allowing the culture to settle. In some experiments, goat anti-mouse IgGs were added simultaneously at a concentration of 10-7 M. Control antibodies, including unrelated mouse monoclonal IgGl and IgG2a K antibodies, were used in the same experimental conditions. The culture supernatants were collected on various days after the beginning of the culture and frozen for thymulin evaluation.
For blocking experiments, human PRL (Techland, Liege, Belgium) used at 10-8 M was added to the medium. TECs were incubated either with human PRL alone, or with human PRL plus the anti-PRL receptor mAb or the anti-PRL receptor mAb alone. Supernatants were stored for thymulin determination.
Proliferation Assay for TECs. Cycling of TECs growing in vitro was assayed by the BrdUrd incorporation assay, similarly to what we have described (27) . The rat TEC line was treated with various anti-PRL receptor mAbs for 1 day and then subjected to 10 mM BrdUrd for 30 min at 37°C. Cultures treated with unrelated mAbs were used as controls. Cells were then fixed in 70% ethanol and subsequently treated with 4M HCO and Na2B207. After washing in PBS, specimens were incubated with the anti-BrdUrd mAb that was further revealed with the fluorescein isothiocyanate-conjugated goat anti-mouse antiserum. At least 1000 cells were counted in three separate experiments.
Statistical Analysis. Differences in thymulin concentrations were assessed by Student's t test and Duncan's multiple range test. Data are expressed as means + SEM.
RESULTS
Detection of Rat PRL Receptor in TECs. Immunocytochemical labeling offrozen sections ofrat thymus with all anti-PRL receptor mAbs consistently revealed a positive signal. Such immunoreactivity was essentially restricted to the medulla of thymic lobules and exhibited a network labeling pattern virtually comprising all medullary TECs (Fig. la) . A doublelabeling immunofluorescence staining using an anti-thymulin mAb demonstrated the same pattern (data not shown). Moreover, cultured rat TECs could also be stained with the anti-PRL receptor mAbs (Fig. lb) .
Immunoblot studies with the anti-PRL receptor mAbs applied to rat TEC line-derived extracts revealed a protein band with a molecular mass of 43 kDa (Fig. ic) .
The specificity of both immunocytochemical and immunoblot labeling was ascertained by the absence of reactivity when the anti-PRL receptor mAbs were previously incubated with an enriched fraction of PRL receptor (Fig. ic) . Preincubation of the antibodies with equivalent amounts of bovine Medical Sciences: Dardenne et al. . The x-ray film was exposed for 4 days with an intensifying screen at -70"C. The filter was then stripped and rehybridized with a complementary RNA probe specific to the short form of PRL receptor (lane 1). Molecular size markers (kb) are indicated on the left and the size of the mRNA transcripts (kb) are indicated on the right. serum albumin did not lead to any attenuation of the signal (data not shown).
Northern blot analysis (Fig. 1d ) revealed a major PRL receptor transcript of 6.7 kb, with a minor transcript of 10.1 kb, when a probe specific to the long form of the PRL receptor was used. When a probe specific to the short form ofthe receptor was used (lane 1), the 10.1-kb band was clearly identified.
In Vitro Effects of anti-PRL Receptor mAbs on Thymulin Production. The effects of various anti-PRL receptor mAbs on thymulin production by the rat TEC line were tested by measuring thymulin levels in culture supernatants after addition to the culture of the mAbs, either alone or simultaneously with anti-mouse immunoglobulins. As shown in Fig. 2 tion that did not stimulate thymulin production, two mAbs, T1 and T6, in the presence of PRL, were able to prevent the biological activity of the hormone, thus demonstrating the blocking capacity of these antibodies (Fig. 3) . Control mAbs did not alter thymulin production by TECs (data not shown).
Anti-PRL Receptor mAbs Stimulate TEC Proliferation. Since the anti-PRL receptor mAbs were able to mimic the effect of PRL in terms of thymulin production, we assayed whether these reagents could also modulate TEC proliferation in vitro as does PRL. The BrdUrd uptake immunofluorescence assay revealed a significant (P < 0.001) increase in the number of BrdUrd-positive cells in anti-PRL receptor mAb (U5 and U6)-treated TEC cultures as compared to control mAb-treated cells (Fig. 4) .
Anti-Rat PRL Receptor mAbs Recognize the PRL Receptor in Human TECs. To determine whether the mAbs raised against the rat PRL receptor were able to recognize the receptor in human TECs, we carried out both immunochemical and biological assays on human thymus or cultured TECs. Immunocytochemistry revealed positive labeling of human TECs in thymus frozen sections (Fig. 5 Upper) and a 43-kDa protein band on thymus-derived extracts (data not shown). Furthermore, all these mAbs were able to modulate thymulin production by cultured human TECs, resulting in a PRL-like stimulatory effect (Fig. 5 Lower) . Interestingly, the concentrations that were the most effective on human cells were also the most active in stimulating thymulin in rat TECs. (28) (29) (30) . Virtually all ofthese reports focused on lymphocytes from peripheral blood or spleen or some lymphocyte cell lines (28) (29) (30) (31) . However, to our knowledge, no study has yet been carried out on PRL receptors in microenvironmental cell types of lymphoid organs.
Earlier studies failed to demonstrate PRL receptors in thymic extracts (25) . In those studies, crude membrane extracts were used. It is well-known that >90%o of the cells in this organ are thymocytes. Thus, it is quite likely that the actual number of TEC-derived membrane components in these total extracts was too low. In contrast, positive immu- figure. C, control; (20, 25) . Although an mRNA transcript encoding the long form of the receptor is present in TECs, it was not identified by immunoblot analysis. Nor was the 84-kDa dimer of the small form observed. The rat ovary, which contains a majority of the long form of the PRL receptor (24) , showed major bands at 84, 51, and 41-43 kDa (17) . This was interpreted as indicating that the majority of the long form of PRL receptor in the rat ovary was degraded to a molecular mass of 51 and 41-43 kDa, in addition to a normal monomer and dimer of 42 and 84 kDa for the small form of PRL receptor. It is thus possible that during the preparation ofmembrane fractions from TECs, the receptor protein of the long form could have been degraded. Alternatively, in both the ovary and TECs, there could be natural posttranslational processing resulting in the smaller form of the receptor predominating, as appears to be the case for the rabbit mammary gland (32) .
An interesting aspect of the present results is the ability of the mAbs to interact with an epitope conserved in both rat and human thymuses. This is in contrast to the relative species specificity of these mAbs, which have been previously reported (18) . Nonetheless, at least for the thymus, they may represent a useful tool for further studies on the structuralfunctional relationships of the human PRL receptor.
These observations, taken together, suggest a heterogeneity in PRL receptors in various cell types. To fully understand the structural differences of the various receptors, molecular cloning ofthe TEC PRL receptor in both rats and humans will be necessary.
As we have previously demonstrated for PRL itself (12) , the mAbs were able to enhance thymic hormone production and TEC proliferation in vitro. Thymulin levels in TEC culture supernatants were consistently increased after treatment with anti-PRL receptor mAbs, usually with an optimal stimulatory antibody concentration reaching from 10-8 to 10-10 M. Interestingly, this effect was enhanced by the addition to the culture medium of anti-mouse IgG. This is similar to previous data by Shiu et (36) .
Lastly, the present observations lend further support to the general concept of the existence of neuroendocrine immune circuits and, in particular, to the neuroendocrine control of thymic function. Specifically, the role of PRL as an immunomodulatory hormone is extended. Thus, both PRL and the closely related hormone, growth hormone, could have pleiotropic actions in the immune system, not only on lymphocytes, triggering a series of activities, such as cell proliferation and interleukin 2 production (33, (37) (38) (39) (40) , but also on cells of the thymic microenvironment. In this respect, two points deserve further discussion. It was previously demonstrated that PRL/GH-secreting cells, when injected into old rats, were able to restore the atrophic thymus to a size normally found in young animals (38, 41) . This effect might be at least partially due to TEC-dependent stimulatory circuits as, for example, thymulin secretion. In this vein, we recently showed that thymulin-containing TEC supernatants were able to enhance thymocyte proliferation (42) . In addition, PRL activities on the thymus seem to be related to a direct effect of the hormone on thymocytes by enhancing c-myc protooncogene expression and DNA synthesis (43) . One question that remains to be answered is whether PRL acts in an endocrine and/or paracrine fashion in the thymus. PRL has been shown to be produced by splenic T cells (44, 45) as well as by certain sublines of IM9 lymphocytes (46) . Thus, potentially, PRL produced by thymocytes could directly affect TECs.
